leisure time -WSS

leisure time

author：focus 2025-09-27 13:04:45 - browse：87

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Chamber of Commerce, DOJ clash in court over drug prices

explore

hotspot

WSS

Quicker fix for pulse oximeters urged during FDA public meeting

White House Covid adviser calls on docs to combat misinformation

Vertigo drug brings hope for rare neuron disorder, Niemann

Cybersecurity threat forces Lurie Children's to take systems offline

Time to name cancers by genetics, not organ of origin, expert says

FDA panel to weigh safety of artificial wombs for preterm births

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Bright Health sells Medicare Advantage business to Molina

Chamber of Commerce, DOJ clash in court over drug prices

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Malaria cases in Florida and Texas: Here’s what you need to know

Why the drug industry's warnings on the IRA's impact fall short

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Eli Lilly CEO gives to Mike Pence presidential super PAC

Wikipedia

New Ultima Genomics DNA sequencer can read genome for $100

Free Covid tests will again be offered to all U.S. households

Juul spent big to court Black leaders to promote its e

New Ultima Genomics DNA sequencer can read genome for $100

Time to name cancers by genetics, not organ of origin, expert says

Chamber of Commerce, DOJ clash in court over drug prices

explore

hotspot

focus

focus